Introduction

P r i m a r y t r a c h e o b r o n c h i a l n e o p l a s m s r e p r e s e n t
approximately 0.1% of all pulmonary tumors (1) . They have been a topic of interest for many decades due to the challenge in their diagnosis and management. Many of tracheobronchial tumors are found incidentally. They are sometimes misdiagnosed as asthma or chronic obstructive pulmonary disease. The past few decades have seen an increase in the diagnosis of these tumors due to the rising popularity of flexible bronchoscopy and advancement in related techniques. We present a review of rare airway tumors (RATs) that have been presented in the literature as case reports or case series and discuss pertinent aspects of the different airway tumors with focus on epidemiology, pathology and genetics, clinical presentation, diagnosis, treatment and outcomes. The Cochrane Library and Medline from 1990 to 2015 was searched to identify the rare airway tumors and to provide a comprehensive review for tumors of the tracheobronchial tree that are considered rare. Following search terms were used: rare airway tumor, tracheal tumors, and rare bronchial tumors. We have focused on rare neoplasms based on incidence and atypical presentation that arise in the tracheobronchial tree from the subglottic to the segmental bronchioles. These tumors were classified based on cell type as well as metastatic potential (Table 1 ) (1) .
Epidemiology
It is difficult to determine the actual prevalence, geographical distribution, gender predominance, age predominance and associated risk factors of these rare tumors (1) (2) (3) (4) . Furthermore, there is no epidemiological data due to the lack of large prospective or retrospective clinical studies. Through individual review of most up-to-date case reports and reviews of each individual tumor, we present the prevalence of each tumor as percentage of primary pulmonary tumors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) or as number of reported cases as well as gender predominance, age predominance and associated risk factors, Table 2 (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Pathology, genetics and immunohistochemistry
There have been very limited reports on the genetics, pathology and associations of RATs. Some of that information has been an extrapolation based on known pathogenesis of these tumors that occurs in other organs. In this paper, we discuss available information on some of the unique genetic and pathological criteria as well as the associations of some of these rare tracheobronchial tumors.
Pulmonary salivary gland-type tumors account for <1% of pulmonary tumors but are distinct group (29) . Mucoepidermoid carcinoma (MEC) is the most common type ( Figure 1 ) followed by adenoid cystic carcinoma (ACC) (29) .
These tumors are indistinguishable histologically from their salivary gland counterparts. They originate from the submucosal glands of the tracheobronchial tree and have structural homology to the exocrine glands. They can be distinguished by cell type as MEC is composed of mucoid and epidermoid cells that are squamous cells while ACC is composed of cribriform, tubular, or solid growth patterns with monomorphic tumor cells. A recent review on the salivary gland tumor reports the difference in term of immunohistochemistry (IHC) and molecular features between these tumors (30) . Pulmonary MEC was reported to have positive immune sensitivity for p63, p40, cytokeratin (CK)7 and CK5/6 and negative IHC for CK20, thyroid transcription factor-1 (TTF-1), and napsin A (6, 31) . This immunohistochemical distinction is important because adenocarcinoma and adenosquamous carcinoma of the lung are difficult to differentiate from MEC by cytomorphology. On the other hand, ACC was determined to be immunoreactive to pan Cytokeratin, CD117 and proto-oncogene MYB (30) . In term of molecular features, around 40% to 75% of MEC of the head and neck region have shown a characteristic association with translocation, t(11;19)(q21;p13). In one study 24 cases of pulmonary MEC showed a mastermind-like 2 (MAML2) on chromosome 11q21 rearrangement by fluorescence in situ hybridization thus demonstrating an importance of this test in diagnostic work up (31) . Recent review also showed that around 50% of studied ACC demonstrate tumor-specific t(6;9) (q22-23;p23-24) translocation generating a MYB (v-myb avian viral oncogene homolog) proto-oncogene fusion with the transcription factor gene NFIB (nuclear factor IB) (30) .
Another interesting rare malignant airway tumor is the epithelial-myopeithelial carcinoma. P53 gene and adenomatous polyposis coli (APC) gene has been implicated in the pathogenesis of epithelial-myoepithelial carcinoma (32) (33) (34) . Although involvement was shown in a case report, more information is needed to show direct association. The immunohistochemical stain for Ki-67 (a cellular marker for proliferation) revealed increased mitotic activity (32) .
Papilloma is another unusual tumor due to its various cell types and association with human papilloma virus (HPV) (Figure 2) . Papilloma is classified into 3 categories: squamous, glandular and mixed. Squamous cell papillomas have been associated with tobacco smoking as well as HPV (8) . A study by Inamura et al. reported 78% of HPV identification in squamous papilloma while none in mixed and glandular cases suggesting that sub types of papilloma's differ in etiology (8) . Katial et al. found HPV DNA in squamous papilloma (reference). The study by Shibuya et al. and Lang et al. showed that HPV serotype 6 and 11 is the most common type associated with papilloma with low risk of malignant transformation (35, 36) . Go et al. showed that p53 status is not a molecular marker for malignant transformation in papillomas and its expression is variable (37) .
The World Health Organization (WHO) have classified neuroendocrine tumors of the lung into three main entities: carcinoid tumors (typical/atypical), large cell neuroendocrine carcinomas (LCNEC), and small cell carcinomas (SCC) (9) . Classification of typical and atypical carcinoid tumors, LCNEC and SCC are based on the histologic appearance, and presence of necrosis and mitoses (9) . This review focused on typical carcinoid (TC) and atypical carcinoid (AC) tumors. The WHO diagnostic criteria for TC are: a tumor with neuroendocrine (38) . On the contrary, AC are rare (0.1-0.2%) lung tumors; however, metastasis to lymph node (40-50%) or distant sites (20%) are common at presentation. Furthermore, neuroendocrine tumors have also been associated with multiple endocrine neoplasia type I (MEN1), an autosomal dominant disorder associated with the gene locus on 11q13.
In one series around 5% of patient with MEN1 were associated with pulmonary carcinoid, while higher incidence of 31% was reported in another study (39) . Inactivation of the MEN1 gene by mutation is evident in TC (47%), AC (70%), LCNEC (52%), and SCLC (41%) (40) (41) (42) . Onuki et al. noted that 11q13 gene mutation was more common in LCNEC (71%) and SCLC (67%). Abnormal expression or loss of heterogenosity and point mutations of the p53 locus have been detected less commonly in TC (4%) than AC (29%) (43, 44) . Expression of p53 protein in AC is correlated with a higher apoptotic index. An older study reports 10q and 13q sequences and allow further cytogenetic differences between AC and TC (45) . Leiomyoma is a benign tumor, which arises from smooth muscle fibers surrounding the airway or in the blood vessels. Multiple cases of leiomyoma have been reported in patients with HIV/AIDS and cellular immunity deficiency (46) . Along with HIV virus, leiomyoma have been reported in immunocompromised patients with Epstein-Barr Virus (47, 48) . Inflammatory myofibroblastic tumors (IMT) are distinctive tumors composed of myofibroblastic spindle cell population as well as inflammatory infiltrate of plasma cells, lymphocytes and eosinophils. The etiology for this tumor is not well understood but many believe it is initiated due to an inflammatory process like trauma or surgery and even infection (49) . One study suggests COX2 and VEGF, as mediators of angiogenesis, which may play a role in the pathogenesis and growth of IMT (50) . In the past couple of years, IMT have got recognition as true tumors than inflammatory process due to reported cases showing presence of clonal chromosomal abnormalities of 2p23 and rearrangement of the anaplastic lymphoma kinase (ALK) receptor tyrosine-kinase gene locus or fusion of ALK with the clathrin heavy chain gene localized on 17q23 (51, 52) .
Diagnosis
Clinical presentation
Many of the RATs are diagnosed incidentally on computed tomogram (CT) imaging or bronchoscopy. Although they tend to have similar clinical presentation and course, RATs may present with different degree of symptomatic severity, depending on the location, size, degree of obstruction, growth rate, and other characteristics of these neoplasms . However, when symptomatic, they all share common constellation of signs and symptoms attributed to tracheobronchial obstruction (Figure 3) . Most RATs present with cough and dyspnea, and sometimes with hemoptysis, wheezing and stridor. Other less common symptoms include pleuritic chest pain, hoarseness and dysphagia (1) . Associated signs include hypoxia, wheezing and stridor.
In some cases, RATs may be misdiagnosed as asthma or chronic obstructive pulmonary disease especially when the onset of symptoms is gradual.
Diagnostic radiology and bronchoscopy
Conventional chest radiographs are not usually diagnostic, yet are commonly obtained as the initial radiological test. Chest CT is the most useful radiologic method to assess the airway tumors and to delineate the extraluminal extent of the tumor (5). MRI provides no clear advantage over CT in the assessment of airway tumors, except for those with salivary gland-type tumors (53) . In those cases, MRI T1-weighted imaging provides better visualization of the glands hyper-intense fatty tissue and delineates the border of the tumor. Pulmonary function testing can be sometimes helpful if there is presence of obstructive pattern or abnormal flow-volume loops that have characteristic flattening as seen in dynamic extrathoracic/intrathoracic obstruction or fixed airway obstruction (1). Bronchoscopy is the diagnostic modality of choice for airway tumors as it allows for direct visualization for localization, tissue sampling and staging (5,54) The extent of the airway tumor and its relation to the surrounding structure can be evaluated using the radial probe endobronchial ultrasound (RP-EBUS) (55, 56) . Besides, the curvilinear EBUS can be used to evaluate the mediastinal lymph nodes for metastasis (57) . The diagnostic approach for most the rare airway tumors discussed in this review follow the above approach (1-15). There are subtle differences in the diagnostic work-up for these tumors depending on the extent of the disease. General summary of the diagnostic tool and associated findings of each tumor is presented below ( Table 3 ) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (30) (31) (32) (33) 36, 38, 48, 58, 59 ) .
Treatment
The treatment of airway tumors requires a multi-disciplinary approach. The interventional pulmonologist, surgeon, anesthesiologist and pathologist all play a crucial role in the management of these tumors. While the treatment of these tumors is complex, good short and long-term outcomes that are possible with a well-planned and well-executed treatment paradigm justify the effort involved.
The first step in the treatment includes a diagnostic classic example of this situation is a carinal tumor that near-obstructs the left mainstem bronchus.
As the surgical approach would be through a right thoracotomy, intubation of the left mainstem to obtain lung isolation is critical. In this situation, the optimal approach would be to open up the left mainstem with multimodality bronchoscopic techniques, place an endotracheal tube in the left mainstem bronchus to obtain good lung isolation and then approach the resection via right thoracotomy. Bronchoscopic destruction of endobronchial tumors can be accomplished in several ways. These include electrocautery, cryotherapy, argon plasma coagulation (APC), and laser (light amplification by stimulated emission of radiation) using Neodymium-Yttrium-AluminumGarnet (Nd:YAG), Neodymium-Yttrium-AluminumPerovskite (Nd:YAP), carbon dioxide lasers and others (60) . Electrocautery involves tissue destruction using an electric current. It is best suited for small intraluminal tumors in early stages with curative intent (61) . It has risk of intraluminal bleeding and perforation. APC, on the other hand, is a mode of noncontact electro-coagulation that involves forming plasma at the tip of a probe which produces coagulative necrosis in the targeted tissue (61) . APC is useful in targeting lesions at sharp angles and provides excellent hemostasis. Laser therapy is useful for tumor debulking and among other used laser types, Nd:YAG is the most commonly used (61) . Nd:YAG Laser has an invisible beam with wavelength that lies in the infrared region with depth up to 10 mm (compared to 1-5 mm for APC). With the exception of the carbon dioxide laser that requires rigid bronchoscopy, most other laser types can be used through the flexible bronchoscope. In contrast, cryotherapy relies on the repeated freeze-thaw cycles using extremely cold temperatures to destroy tumor tissue (61) . Cryotherapy results in both physical and vascular damage of the tumor. It has very low risk of bleeding and perforation. Airway dilation using sequential balloon or rigid bronchoscopy techniques is another approach that is usually used in combination with other bronchoscopic modalities or as a palliative measure to maintain airway patency (61) .
The factors that impact the successful bronchoscopic intervention are the extension of the tumor to the distally beyond the central airways, complex tumors with wider mucosal extension (more than three bronchial rings), bronchial wall invasion toward other mediastinal structures, and determining cartilage invasion with radial probe EBUS (54) . Endoscopic approach is preferred over surgical approach in patients with multiple co-morbidities and high surgical risk. Other treatment such as chemotherapy, radiotherapy and anti-inflammatory drugs may be used in conjunction with surgical or endoscopic management or as palliation for patient who have tumors that are candidates for endoscopic or surgical management (3, 4, 6, 7, 9, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . A summary of most employed treatment modalities for rare airway tumors is provided in Table 4 (26, 32, 36, 47, 49, (58) (59) (60) (62) (63) (64) (65) (66) (67) .
Surgical treatment is aimed at obtaining negative surgical margins while sparing as much lung parenchyma as possible. In tumors distal to the carina, sleeve resection is preferred over pneumonectomy whenever feasible. In lesions at or proximal to the carina, often, complete sparing of all lung parenchyma is possible. While it is beyond the scope of this article to discuss the details of all possible combinations of resection, it is important to note that the resections should be carefully planned by an experienced team that includes the interventional pulmonologist, surgeon and anesthesiologist. All patients should be planned on being extubated on the table. The interventional pulmonologist's involvement continues into the post-operative period in order to handle post-resection stenosis, even though this should be rare (<5%).
Outcomes
The overall survival of rare airway tumors depends on multiple factors including tumor malignant potential, patient's co-morbidities, location, and risks of treatment modality. Benign tumors are usually localized and amendable to resection with no or minimal risk of recurrence (1) . Benign tumors are usually treated with surgical resection with very low recurrence rate. Tumors that are treated with endoscopic excision have varying degrees of recurrence, but re-excision is usually feasible (1, 54, 62) . Imaging and bronchoscopy are usually used to survey for possible recurrence (5, 54) . The outcome of malignant tumors is variable and depends on location, lymph node involvement and mediastinal invasion of vital organs (1, 26) . • tracheal sleeve resection
• segmental tracheal resection (anastomotic failure due to dehiscence and stenosis)
• carinal resection
• endoscopic resection 
